MedTrace Logo

Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin

NCT01341717 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2014-05-30

No results posted yet for this study

Summary

The purpose of the study is to determine the efficacy and safety of sitaglipin in the treatment of Type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control using metformin and insulin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sitagliptin

100 mg once daily for 6 months

DRUG

Glimepiride

1 mg/2 mg/3 mg once daily

DRUG

Metformin

\>=1000 mg twice daily

DRUG

Insulin

TDD \> 10 IU once/twice daily

Sponsors & Collaborators

  • Jothydev's Diabetes and Research Centre

    lead OTHER

Principal Investigators

  • Jothydev Kesavadev, MD · Jothydev's Diabetes and Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341717 on ClinicalTrials.gov